Marpai, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Marpai, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Marpai, Inc. has logged 84 insider filings. Market capitalisation: €59.9m. The latest transaction was reported on 2 June 2026 (Disposition). Among the most active insiders: EITAN YARON. All data is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,552 of 29,064 companies
FCF yld -25%
Earn yld -45%
EV/EBITDA ·
ROE ·
Gross mgn 35%
Net mgn -77%
Debt/EBITDA ·
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 June 2026
All Executives84 Thresholds0 Prospectus0 Other0
Declarations 84 total
● Director · Executives · 8 Dec 2025
50,000 shares 0Class A Common Stock SEC:0001213900-26-064249:0
◆ Director · Executives · 29 May 2026
100,000 shares 0Class A Common Stock SEC:0001213900-26-064249:1
▲ Director · Executives · 20 May 2026
10,000 shares @ US$0.27 0.018% mcap 0.3% of flow Class A Common Stock SEC:0001213900-26-060552:0
Canonical exit: 18 Aug 2026 (T+90) ◆ Director · Executives · 19 Feb 2026
100,000 shares 0Class A Common Stock SEC:0001213900-26-041486:0
▲ Director · Executives · 7 Nov 2025
50,000 shares @ US$1.00 49.6% of flow Class A Common Stock SEC:0001213900-25-108613:0
Canonical exit: 5 Feb 2026 (T+90) ▲ Director · Executives · 7 Nov 2025
100,000 shares @ US$1.00 10.5% of flow Class A Common Stock SEC:0001213900-25-108618:0
Canonical exit: 5 Feb 2026 (T+90) ▲ Director · Executives · 7 Nov 2025
50,000 shares @ US$1.00 100.0% of flow Class A Common Stock SEC:0001213900-25-108615:0
Canonical exit: 5 Feb 2026 (T+90) ◆ Chief Operating Officer · Executives · 7 Nov 2025
100,000 shares @ US$1.00 100.0% of flow Class A Common Stock SEC:0001213900-25-108614:0
◆ Chief Executive Officer · Executives · 20 Oct 2025
550,000 shares 0Class A Common Stock SEC:0001213900-25-101346:0
◆ Director · Executives · 20 Oct 2025
75,000 shares 0Class A Common Stock SEC:0001213900-25-101344:0
◆ Director · Executives · 20 Oct 2025
125,000 shares 0Class A Common Stock SEC:0001213900-25-101342:0
◆ Director · Executives · 20 Oct 2025
50,000 shares 0Class A Common Stock SEC:0001213900-25-101340:0
◆ Chief Financial Officer · Executives · 20 Oct 2025
275,000 shares 0Class A Common Stock SEC:0001213900-25-101338:0
◆ Director · Executives · 20 Oct 2025
50,000 shares 0Class A Common Stock SEC:0001213900-25-101336:0
◆ Director · Executives · 20 Oct 2025
75,000 shares 0Class A Common Stock SEC:0001213900-25-101334:0
10,000 shares @ US$1.43 100.0% of flow Common Shares, par value $0.0001 SEC:0001798792-25-000010:0
▲ Chief Executive Officer · Executives · 30 Sept 2025
147,058 shares @ US$1.36 3.0% of flow Class A Common Stock SEC:0001213900-25-095500:0
Canonical exit: 29 Dec 2025 (T+90) ▲ Chief Executive Officer · Executives · 10 Sept 2025
896,903 shares @ US$1.0592 14.5% of flow Class A Common Stock SEC:0001213900-25-092326:0
Canonical exit: 9 Dec 2025 (T+90) ◆ Director · Executives · 19 Aug 2025
75,000 shares 0Class A Common Stock SEC:0001213900-25-088222:0
◆ Director · Executives · 19 Aug 2025
75,000 shares 0Class A Common Stock SEC:0001213900-25-088221:0
◆ Director · Executives · 19 Aug 2025
75,000 shares 0Class A Common Stock SEC:0001213900-25-087420:0
◆ Director · Executives · 19 Aug 2025
75,000 shares 0Class A Common Stock SEC:0001213900-25-087419:0
◆ Director · Executives · 19 Aug 2025
75,000 shares 0Class A Common Stock SEC:0001213900-25-087417:0
▲ Chief Executive Officer · Executives · 29 Jul 2025
371,470 shares @ US$1.0768 7.2% of flow Class A Common Stock SEC:0001213900-25-070792:0
Canonical exit: 27 Oct 2025 (T+90) ▲ Chief Executive Officer · Executives · 17 Jul 2025
86,805 shares @ US$1.152 1.9% of flow Class A Common Stock SEC:0001213900-25-066103:0
Canonical exit: 15 Oct 2025 (T+90) 25 of 84 declarations
Load more (59 remaining) 关于 Marpai, Inc. Marpai, Inc. 是一家总部位于美国佛罗里达州坦帕市的美国医疗保健服务和技术公司。该公司股票此前在纳斯达克资本市场上市,股票代码为 MRAI,之后公司将交易转移至 OTCQX 市场。对于投资者而言,Marpai 最好被理解为一家专注于自保型雇主健康计划的小盘医疗保健管理平台,其运营模式围绕技术赋能的福利管理和邻近的药房服务而构建。
Marpai 业务的核心是为自保型雇主提供第三方管理(TPA)服务。通过其子公司,该公司为健康和福利计划提供后台管理,包括索赔管理、受抚养人资格验证、COBRA 管理、福利账单以及相关的呼叫中心支持。该公司强调这些服务由定制的技术平台提供支持。Marpai 还强调利用人工智能更早地识别高风险成员,将他们与临床解决方案联系起来,并引导他们选择成本较低的网络内提供商。实际上,该公司销售的是行政外包、分析和护理导航工具的组合,旨在帮助雇主管理医疗保健支出。
Marpai 的公司历史反映了其相对较近的成立和持续的战略调整。公开文件显示,Marpai Captive 于 2022 年 3 月作为一家特拉华州公司成立,这突显了该公司努力将其生态系统扩展到传统 TPA 工作之外。最近,Marpai 通过其药房福利管理计划 MarpaiRx 扩大了其业务范围。这一举措具有战略重要性,因为 PBM 能力可以深化客户关系,增加经常性收入潜力,并为雇主赞助的医疗保健提供另一个成本控制杠杆。
竞争定位是关键考量。Marpai 在一个庞大但竞争激烈且分散的市场中运营,在这个市场中,规模至关重要,而规模较大的全国性管理者和福利经理通常享有更强的购买力、更广泛的网络和更成熟的分销渠道。因此,Marpai 的差异化是小众而非普遍的:它针对自保型雇主,推广以技术为主导的运营模式,并寻求通过更智能的索赔管理和成本优化而非单纯的规模来赢得业务。该公司的竞争优势取决于执行力、客户获取能力以及将其技术主张转化为可衡量的客户节省的能力。
最近的发展表明运营状况正在改善。2026 年 5 月,Marpai 宣布在 TPA 和 MarpaiRx 方面取得了显著的新业务成功,并表示这些成功巩固了其盈利前景。2026 年 3 月,该公司还披露了一项旨在扩大 MarpaiRx 覆盖范围的营销协议。在其最新的沟通中,管理层强调了成本纪律、运营改进以及实现盈利的途径。对于市场参与者而言,Marpai 仍然是一个扭亏为盈的故事,而不是一个成熟的医疗保健巨头,但它在美国市场拥有清晰的战略重点和可识别的催化剂。